François Nader, M.D., serves as Chairman at BenevolentAI. From 2008 to 2015, Dr Nader was President, Chief Executive Officer, and Executive Director of NPS Pharma, a global biotechnology company focused on innovative rare disease therapies. He was an integral part of engineering its sale to Shire. Prior to NPS, Dr Nader was a partner at Care Capital, a venture capital firm. He previously served on the North America Leadership Team of Aventis Pharma and its predecessor companies, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. He also led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr Nader currently serves as the Chairman of Talaris, Acceleron Pharma and non-executive Board Director at Moderna and Alexion.
Dr Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon and a physician executive MBA from the University of Tennessee. Dr Nader is a member of the Audit and Finance Committee and the Science and Innovation Committee.